Theravance Biopharma (NASDAQ:TBPH - Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26), Zacks reports. The firm had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%.
Theravance Biopharma Price Performance
TBPH traded up $0.08 on Friday, reaching $9.35. 1,271,580 shares of the company traded hands, compared to its average volume of 239,782. The company has a market cap of $459.78 million, a price-to-earnings ratio of -9.26 and a beta of 0.21. The stock's 50 day moving average price is $9.33 and its 200-day moving average price is $8.93. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $10.90.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $13.75.
Read Our Latest Stock Report on TBPH
Insider Buying and Selling
In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares of the company's stock, valued at approximately $2,786,085. The trade was a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.90% of the stock is owned by corporate insiders.
Theravance Biopharma Company Profile
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Further Reading
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
